date:Mar 27, 2013
s late as 10 days.
This heptavalent antitoxin is the only product available for the treatment of botulism in adults, and for cases of infant botulism caused by nerve toxins other than types A and B.
The effectiveness of the product was studied in animals because it was not feasible or ethical to conduct efficacy studies in humans. The results provided substantial evidence that the antitoxin is reasonably likely to benefit humans with botulism. Under the FDAs Animal Rule, the agency may approve